Diversify Wealth Management LLC Purchases New Holdings in AstraZeneca PLC $AZN

Diversify Wealth Management LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 2,869 shares of the company’s stock, valued at approximately $234,000.

Other hedge funds also recently modified their holdings of the company. Brighton Jones LLC boosted its position in AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after acquiring an additional 2,789 shares during the period. AQR Capital Management LLC lifted its position in shares of AstraZeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after purchasing an additional 11,690 shares in the last quarter. World Investment Advisors boosted its holdings in shares of AstraZeneca by 36.0% during the second quarter. World Investment Advisors now owns 10,752 shares of the company’s stock worth $751,000 after purchasing an additional 2,844 shares during the period. Arkadios Wealth Advisors grew its position in AstraZeneca by 20.2% during the second quarter. Arkadios Wealth Advisors now owns 11,195 shares of the company’s stock valued at $782,000 after purchasing an additional 1,884 shares in the last quarter. Finally, Simon Quick Advisors LLC grew its position in AstraZeneca by 9.4% during the second quarter. Simon Quick Advisors LLC now owns 8,720 shares of the company’s stock valued at $609,000 after purchasing an additional 751 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of AZN stock opened at $208.72 on Monday. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. The stock’s fifty day simple moving average is $135.91 and its 200 day simple moving average is $102.37. AstraZeneca PLC has a one year low of $122.48 and a one year high of $212.71. The firm has a market cap of $323.71 billion, a price-to-earnings ratio of 69.34, a P/E/G ratio of 1.59 and a beta of 0.34.

AstraZeneca Announces Dividend

The company also recently announced a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be given a dividend of $1.595 per share. The ex-dividend date is Friday, February 20th. This represents a dividend yield of 156.0%. AstraZeneca’s dividend payout ratio (DPR) is 74.83%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of AstraZeneca in a research note on Friday, February 6th. HSBC restated a “buy” rating and issued a $108.00 target price on shares of AstraZeneca in a research note on Wednesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Wednesday, December 3rd. Barclays reissued an “overweight” rating on shares of AstraZeneca in a research note on Tuesday, January 6th. Finally, Wall Street Zen downgraded shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 17th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.